Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
BMC Pediatr ; 24(1): 344, 2024 May 18.
Artículo en Inglés | MEDLINE | ID: mdl-38760745

RESUMEN

BACKGROUND: Paediatric patients are especially prone to experiencing adverse drug reactions (ADRs), and the surgical environment gathers many conditions for such reactions to occur. Additionally, little information exists in the literature on ADRs in the paediatric surgical population. We aimed to quantify the ADR frequency in this population, and to investigate the characteristics and risk factors associated with ADR development. METHODS: A prospective observational study was conducted in a cohort of 311 paediatric patients, aged 1-16 years, admitted for surgery at a tertiary referral hospital in Spain (2019-2021). Incidence rates were used to assess ADR frequency. Odds ratios (ORs) were calculated to evaluate the influence of potential risk factors on ADR development. RESULTS: Distinct ADRs (103) were detected in 80 patients (25.7%). The most frequent being hypotension (N = 32; 35%), nausea (N = 16; 15.5%), and emergence delirium (N = 16; 15.5%). Most ADRs occurred because of drug-drug interactions. The combination of sevoflurane and fentanyl was responsible for most of these events (N = 32; 31.1%). The variable most robustly associated to ADR development, was the number of off-label drugs prescribed per patient (OR = 2.99; 95% CI 1.73 to 5.16), followed by the number of drugs prescribed per patient (OR = 1.26, 95% CI 1.13 to 1.41), and older age (OR = 1.26, 95% CI 1.07 to 1.49). The severity of ADRs was assessed according to the criteria of Venulet and the Spanish Pharmacovigilance System. According to both methods, only four ADRs (3.9%) were considered serious. CONCLUSIONS: ADRs have a high incidence rate in the paediatric surgical population. The off-label use of drugs is a key risk factor for ADRs development.


Asunto(s)
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Humanos , Estudios Prospectivos , Niño , Preescolar , Femenino , Masculino , Factores de Riesgo , Lactante , Adolescente , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , España/epidemiología , Procedimientos Quirúrgicos Operativos/efectos adversos , Incidencia , Interacciones Farmacológicas , Uso Fuera de lo Indicado , Delirio del Despertar/epidemiología , Delirio del Despertar/inducido químicamente
2.
Rev Esp Salud Publica ; 74(4): 351-9, 2000.
Artículo en Español | MEDLINE | ID: mdl-11031843

RESUMEN

BACKGROUND: Amphotericin B is the treatment of choice for systemic fungal infections, however, its clinical usefulness is limited by its toxicity. The lipid formulations appear to be equally effective and safer, but are more costly. The increase in the consumption of, and expenditure on these formulas led us to undertake a study in order to identify their profile of use (quantitative and qualitative) and to assess the financial repercussions when used inappropriately. METHODS: A set of rules were developed for the use of amphotericin B, and the quality of the prescription of non-conventional amphotericin B (amphotericin B notC) was evaluated retrospectively together with the financial repercussions of its inappropriate use. RESULTS: In 54% of the treatments studied, a poor selection of amphotericin B was made; in 3.5%, the use of amphotericin B was not indicated. The excess expenditure derived from the inappropriate use amounted to 42 million pesetas, 35% of the total expenditure on medicines; the expenditure due to unnecessary prescription was 1,720,327 pesetas. CONCLUSIONS: The retrospective evaluation has shown that there is a high percentage of treatments that do not conform with the recommendations contained in the prescription rules. The holding of information sessions would assist in achieving a more efficient selection of the amphotericin B notC; this would improve prescription quality, which might also deliver significant financial savings.


Asunto(s)
Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Micosis/tratamiento farmacológico , Anfotericina B/economía , Antifúngicos/economía , Química Farmacéutica , Costos de los Medicamentos , Utilización de Medicamentos , Humanos , Estudios Retrospectivos , España
3.
Rev Esp Salud Publica ; 75(4): 353-60, 2001.
Artículo en Español | MEDLINE | ID: mdl-11693073

RESUMEN

BACKGROUND: Amphotericin B is the treatment of choice for systemic fungal infections. Among the different AB formulations available, the lipid forms appear to have a better profile of reliability, however, their cost is noticeably higher. In 1999 (pre-initiative period) an evaluation of the quality of the prescription of these preparations was made in our hospital, which revealed that they were not being used to best advantage and were responsible for generating a significant unnecessary expenditure. As a result of this, an information initiative was implemented with respect to the prescribing physicians for the purpose of reducing the inappropriate use of AB. METHOD: The quality of 100 prescriptions was evaluated prospectively, according to the standards of use of Amphotericin B established in the hospital. Following each evaluation, a pharmacologist personally handed over to each prescribing physician a set of rules governing the use of the Amphotericin B, discussing the indication and recommending the best alternative in each case. In order to measure the impact of this initiative, the appropriateness of the prescriptions during this period was compared with the pre-initiative period. RESULTS: The percentage of inappropriate prescriptions dropped from 58% to 21% following the implementation of the initiative. Likewise, a 33-million-peseta reduction in the total expenditure was achieved in 15 months as well as a savings of 24 million in inappropriate prescriptions. CONCLUSIONS: The information initiative improved the quality of the prescribing of preparations of Amphotericin B associated with lipids and considerably reduced the unnecessary expense associated with Amphotericin B misuse in our hospital.


Asunto(s)
Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Prescripciones de Medicamentos/estadística & datos numéricos , Hospitales Urbanos , Humanos , Estudios Prospectivos , España
4.
Rev Clin Esp ; 189(5): 221-3, 1991 Oct.
Artículo en Español | MEDLINE | ID: mdl-1801070

RESUMEN

A patient who had been successfully treated of Hodgkin's disease (nodular sclerotic type) with mediastinal radiotherapy and polychemotherapy, suffered an acute pericarditis immediately after radiotherapy and a complete atrial-ventricular block 14 years later. Five years later she presented refractory hemorrhagic peritonitis. Necropsy study showed a peritoneal mesothelioma (in non radiated area) and diffuse subpericardial fibrosis. Complete A-V block is a very rare late complication of mediastinal radiotherapy and mesotheliomas (almost exclusively in irradiated areas), also. We have not found any reports on other cases of peritoneal mesotheliomas not attributable to radiotherapy as second neoplasia in Hodgkin's disease.


Asunto(s)
Bloqueo Cardíaco/etiología , Enfermedad de Hodgkin/complicaciones , Mesotelioma/etiología , Neoplasias Peritoneales/etiología , Femenino , Bloqueo Cardíaco/patología , Enfermedad de Hodgkin/patología , Enfermedad de Hodgkin/radioterapia , Humanos , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/secundario , Metástasis Linfática , Mesotelioma/patología , Persona de Mediana Edad , Aceleradores de Partículas , Neoplasias Peritoneales/patología , Factores de Tiempo
5.
Medifam (Madr.) ; 12(6): 369-378, jun. 2002. tab
Artículo en Es | IBECS (España) | ID: ibc-16545

RESUMEN

Las heparinas de bajo peso molecular han de mostrado ser tan eficaces y seguras en la profilaxis del tromboembolismo venoso como la heparina no fraccionada. Su baja unión a proteínas plasmáticas, macrófagos y endotelio contribuye a su excelente biodisponibilidad vía subcutánea, a una respuesta anticoagulante más predecible cuando se administra a dosis fijas y a una vida media mayor. Además su administración subcutánea es más cómoda para el paciente y no se precisan ajustes de dosis. En este trabajo se revisan los principales factores de riesgo del tromboembolismo venoso y los distintos métodos físicos y farmacológicos disponibles actualmente para prevenirlo. También se resumen las últimas recomendaciones publicadas para la profilaxis del TEV en pacientes no quirúrgicos (AU)


Asunto(s)
Femenino , Masculino , Humanos , Tromboembolia/prevención & control , Heparina de Bajo-Peso-Molecular/uso terapéutico , Factores de Riesgo , Profilaxis Antibiótica , Infarto del Miocardio/etiología
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda